About GeneAssess, Inc.
GeneAssess, Inc. is, an early stage biotech company, founded in 2012. The company maintains office space at 120 Albany Street, New Brunswick, NJ 08901. Our current focus is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for cancer patients.
We are developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. In addition, we intend to develop mechanistically-based, percision cancer therapies using FRY signal targeting methodology.
April 2013; GeneAssess, Inc. moving to CCIT Laboratory on April 1st
December 2012; GeneAssess received patent license transfer agreement from University of Medicine and Dentistry of New Jersey.
June 2012; GeneAssess, Inc. was formed as a Delaware “C” corporation. Dr. Helmut Zarbl, Professor/Director of Environmental & Occupational Health Sciences Institute, found GeneAssess, Inc.
June 2012; GeneAssess, Inc. received $500,000 for “validation of FRY gene as a cancer molecular signature gene” from Foundation Venture Capital Group, LLC.